✦ LIBER ✦

Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: Results of a three-arm Phase I study

✍ Scribed by Ronald D. Alvarez; Robert Mannel; Agustin A. García; Holly H. Gallion; Joseph Lucci III; Larry C. Kilgore; Thomas M. Numnum; Sharon Xiaohan Zou; Mauro Orlando; Datchen F. Tai

Book ID: 113962221
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 246 KB
Volume: 115
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2009.09.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Topotecan and carboplatin in patients wi

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

✍ Dominique Koensgen; Dirk Stengel; Antje Belau; Peter Klare; Guelten Oskay-Oezcel 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 324 KB

A randomized phase II study of carboplat

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

✍ Dimitrios Bafaloukos; Helena Linardou; Gerasimos Aravantinos; Christos Papadimit 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 332 KB

165 Gemcitabine (G) plus carboplatin (C)

165 Gemcitabine (G) plus carboplatin (C) in patients whose epithelial ovarian carcinomas (EOC) relapsed ≥ 6 months after platinum-containing first-line therapy: Preliminary results of a phase II study

✍ F. Kose; J. Sufliarsky; S. Beslija; P. Saip; K. Krejcy; T. Minarik; E. Fitzthum; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Phase I trial of fixed dose-rate gemcita

Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study

✍ Ross A. Soo; Hong L. Lim; Ling Z. Wang; How S. Lee; Michael J. Millward; Lay T. 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 198 KB

Phase I/II study of gemcitabine as a fix

Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients

✍ Chigusa Morizane; Takuji Okusaka; Hideki Ueno; Shunsuke Kondo; Masafumi Ikeda; J 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 226 KB

3544 POSTER Phase I study of gemcitabine

3544 POSTER Phase I study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy in gemcitabine-refractory pancreatic cancer patients.

✍ C. Morizane; T. Okusaka; J. Furuse; H. Ishii; H. Ueno; M. Ikeda; T. Ogura; K. Na 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 80 KB